| 1 |
NCT03472183 |
Not yet recruiting |
Exploration of the Enteric Nervous System in Alzheimer Disease |
|
|
Interventional |
Not Applicable |
- Nantes University Hospital
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Differences in extracellular deposits of beta-amyloid peptide in the enteric nervous system between patients with Alzheimer's disease, patients with Parkinson's disease and patients without neurodegenerative disease.
- Differences in tau protein in the enteric nervous system between patients with Alzheimer's disease, patients with Parkinson's disease and patients without neurodegenerative disease.
- Differences in neuronal loss in enteric submucosal tissue between patients with Alzheimer's disease, patients with Parkinson's disease and patients without neurodegenerative disease
- Differences in neuronal Glia cells in the enteric nervous system between patients with Alzheimer's disease, patients with Parkinson's disease and patients without neurodegenerative disease.
|
30 |
All |
50 Years to 80 Years (Adult, Senior) |
NCT03472183 |
RC17_0252 |
SYNEMA |
March 25, 2018 |
November 25, 2020 |
November 25, 2020 |
March 21, 2018 |
March 21, 2018 |
|
|
| 2 |
NCT02672306 |
Not yet recruiting |
Safety and Exploratory Efficacy Study of UCMSCs in Patients With Alzheimer's Disease |
|
- Biological: UCMSCs
- Biological: Placebo
|
Interventional |
Phase 1
Phase 2 |
- South China Research Center for Stem Cell and Regenerative Medicine
- Third Affiliated Hospital, Sun Yat-Sen University
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Guangzhou Psychiatric Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Treatment
|
- Change in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)Score
- Change in Alzheimer's Disease Cooperative Study Clinician's Global Impression of Change (ADCS-CCGIC) Score
- Change in Mini-Mental State Examination (MMSE) Score
- (and 4 more...)
|
40 |
All |
50 Years to 85 Years (Adult, Senior) |
NCT02672306 |
UCMSC-1 |
SEESUPAD |
May 2016 |
October 2018 |
October 2019 |
February 3, 2016 |
February 3, 2016 |
|
|
| 3 |
NCT03408041 |
Completed |
Reported Time Between Onset and Diagnosis of Alzheimer's Disease: Correlation With Objective Parameters |
|
- Other: Medical file data extraction
|
Observational |
|
- Murielle Surquin
- Brugmann University Hospital
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Age
- Sex
- Ethnic origin
- (and 2 more...)
|
129 |
All |
Child, Adult, Senior |
NCT03408041 |
CHUB-parameters Alzheimer |
|
May 1, 2016 |
October 1, 2017 |
October 1, 2017 |
January 23, 2018 |
January 23, 2018 |
|
- CHU Brugmann
Brussels, Belgium
|
| 4 |
NCT01692977 |
Completed |
What Elements of the Design of a Healing Garden Are Used as Landmarks by Patients With Alzheimer's Disease to Locate? |
|
- Other: neuropsychological assessment
|
Interventional |
Not Applicable |
- Central Hospital, Nancy, France
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Analyze nature and frequency of elements of the " art, memory and life " garden used as landmarks by Alzheimer's disease patients
- Study the characteristics of the elements that contributed to decision-making regarding spatial orientation, the cognitive map, correlations between success in experimental, neuropsychological assessment in Alzheimer disease and healthy control subjects.
|
77 |
All |
65 Years to 90 Years (Adult, Senior) |
NCT01692977 |
2011-A00993-38 |
JAZ-TOP |
August 2012 |
October 2014 |
October 2014 |
September 26, 2012 |
July 30, 2015 |
|
- University Hospital of Nancy , Saint Julien Hospital, France
Nancy, France
|
| 5 |
NCT02349191 |
Not yet recruiting |
Omental Transposition Surgery for Mild Alzheimer's Disease |
|
- Procedure: Omental transposition for mild Alzheimers disease
|
Interventional |
Not Applicable |
- Bariatric Medicine Institute, Salt Lake City, UT
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of surgical complications from beginning of anesthesia to discharge from Intensive Care Unit.
- Change in Alzheimer's Disease Assessment Scale - Cognition (ADAS-cog) score from baseline at 12 months.
- Change in Montreal Cognitive Assessment (MoCA) score from baseline at 12 months
- (and 6 more...)
|
25 |
All |
65 Years to 85 Years (Adult, Senior) |
NCT02349191 |
Cottam - 1 |
|
March 2016 |
April 2017 |
May 2019 |
January 28, 2015 |
March 22, 2016 |
|
|
| 6 |
NCT02703636 |
Recruiting |
Study to Evaluate the Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease |
- Mild to Moderate Alzheimer's Disease
|
|
Interventional |
Phase 4 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change from baseline to week 24 in the total score of Mini-Mental State Examination (MMSE)
- Monitoring and recording of all adverse events (AEs) and serious adverse events (SAEs).
- Change from baseline to Week 8 in Mini-Mental State Examination (MMSE) total score.
- (and 5 more...)
|
120 |
All |
50 Years to 85 Years (Adult, Senior) |
NCT02703636 |
CENA713DJP02 |
ENA1stepswitch |
May 10, 2016 |
April 24, 2018 |
April 24, 2018 |
March 9, 2016 |
June 21, 2017 |
|
- Novartis Investigative Site
Fukuoka-city, Fukuoka, Japan - Novartis Investigative Site
Fukuoka-city, Fukuoka, Japan - Novartis Investigative Site
Aizuwakamatsu, Fukushima, Japan - (and 17 more...)
|
| 7 |
NCT00987090 |
Unknown † |
Early-onset and Late-onset Sporadic Alzheimer's Disease (AD) |
|
- Biological: Clinic and neuropsychologic evaluation
- Radiation: MRI
- Procedure: PET
- (and 2 more...)
|
Interventional |
Not Applicable |
- Assistance Publique Hopitaux De Marseille
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- to establish the impact of age on the clinical and neuroimaging picture of sporadic Alzheimer Disease in a multicentric setting.
- to describe for each age group, and in particular for the younger patient group, the functional impact of disability in everyday life on both, patients and caregivers.
|
240 |
All |
45 Years to 90 Years (Adult, Senior) |
NCT00987090 |
2008/24
2008-A01213-52 |
|
October 2009 |
September 2016 |
|
September 30, 2009 |
October 23, 2015 |
|
- Assistance Publique - Hôpitaux de Marseille
Marseille, France
|
| 8 |
NCT03340571 |
Recruiting |
Blood Biomarker of Alzheimer's Disease (AD) |
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Biological marker of Alzheimer's disease
|
60 |
All |
50 Years and older (Adult, Senior) |
NCT03340571 |
Pro00085997 |
|
March 12, 2018 |
August 2018 |
August 2018 |
November 13, 2017 |
March 14, 2018 |
|
- Duke University
Durham, North Carolina, United States
|
| 9 |
NCT03055741 |
Recruiting |
Study of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil |
- Mild-moderate Alzheimer's Disease
|
- Drug: Donepezil
- Drug: DHP1401
- Drug: Placebo
|
Interventional |
Phase 2 |
- Daehwa Pharmaceutical Co., Ltd.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Alzheimer's Disease Assessment Scale-cognition Korean version(ADAS-cog)
- Clinical Dementia Rating Sum of Box Korean version(CDR-SB)
- Neuropsychiatric Inventory-Q Korean version(NPI-Q)
- (and 3 more...)
|
180 |
All |
55 Years to 85 Years (Adult, Senior) |
NCT03055741 |
1401CS-2 |
|
December 28, 2016 |
September 2018 |
September 2018 |
February 16, 2017 |
December 4, 2017 |
|
- The Catholic University of Korea, Bucheon, ST. Mary's Hospital
Bucheon-si, Gyeonggi-do, Korea, Republic of - Myongji Hospital
Goyang-si, Gyeonggi-do, Korea, Republic of - Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, Korea, Republic of - (and 8 more...)
|
| 10 |
NCT00412048 |
Withdrawn |
Functional Magnetic Resonance Imaging - Synthetic Aperture Magnetometry (fMRI-SAM) and Alzheimer's Disease |
|
- Procedure: fMRI to detect MCI patients who will convert to Alzheimer's disease
|
Interventional |
Not Applicable |
- University Hospital, Strasbourg, France
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Comparing fMRI data between 3 groups of subjects: MCI, Alzheimer's disease and normal subjects
- Follow-up of MCI patients at 6, 12 and 18 months to detect a conversion to Alzheimer's disease
|
0 |
All |
55 Years to 75 Years (Adult, Senior) |
NCT00412048 |
3659 |
|
April 2012 |
February 2018 |
February 2018 |
December 15, 2006 |
November 14, 2012 |
|
|
| 11 |
NCT01928420 |
Completed |
A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease |
- Alzheimer's Disease
- Dementia
|
- Drug: Drug: NIC5-15
- Drug: Placebo
|
Interventional |
Phase 2 |
- Humanetics Corporation
- National Center for Complementary and Integrative Health (NCCIH)
- James J. Peters Veterans Affairs Medical Center
|
Industry / NIH / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)Score
- Change in Alzheimer's Disease Cooperative Study Clinician's Global Impression of Change (ADCS-CCGIC) Score
- Change in Mini-Mental State Examination (MMSE) Score
- (and 4 more...)
|
30 |
All |
40 Years to 95 Years (Adult, Senior) |
NCT01928420 |
R21AT003302-01A1
MHBB-009-06S |
|
April 2007 |
June 2014 |
June 2014 |
August 26, 2013 |
October 17, 2016 |
|
- James J Peters Veterans Affairs Medical Center
Bronx, New York, United States
|
| 12 |
NCT02253043 |
Recruiting |
The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Patients With Alzheimer's Disease |
|
- Device: Deep Brain Stimulation (Beijing PINS Medical Co., Ltd)
|
Interventional |
Not Applicable |
- Beijing Pins Medical Co., Ltd
- Beijing Tiantan Hospital
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Alzheimer's Disease Assessment Scale, Cognitive Subscale (ADAS-Cog)
- Clinical Dementia Rating Scale
|
10 |
All |
40 Years to 80 Years (Adult, Senior) |
NCT02253043 |
PINS-002 |
|
May 2014 |
December 2018 |
December 2018 |
October 1, 2014 |
October 14, 2016 |
|
- Beijing Tiantan Hospital
Beijing, Beijing, China - 301 Hospatl
Beijing, Beijing, China
|
| 13 |
NCT02158910 |
Completed |
A Plan on Investigation and Collection of Aricept Safety Information With a Dose Increase on Alzheimer's Disease Patients |
|
|
Observational |
|
- Eisai Korea Inc.
- Eisai Inc.
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Safety and tolerability due to an increase of Aricept in patients with Alzheimer's disease.
|
2231 |
All |
Child, Adult, Senior |
NCT02158910 |
ART-M082-601 |
AID |
March 2015 |
June 2016 |
June 2016 |
June 9, 2014 |
March 7, 2017 |
|
- Busan, Korea, Republic of
- Chungcheongbuk-do, Korea, Republic of
- Chungcheongnam-do, Korea, Republic of
- (and 10 more...)
|
| 14 |
NCT03090854 |
Not yet recruiting |
Cholinergic Markers Alzheimer's Disease |
|
|
Observational |
|
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
- Neuropsychological test (ADASCog)
- Rate of responder AD in this cohort included according to the new AD criteria and comparison of the current rate with the previous rate published using former AD criteria
- Difference of CSF Ach AND AChE activity between responder and non responder groups
- Statistical evaluation of the link between CSF Ach, AChE activity, total and phosphorylated Tau, Aß40 and Aß42.
|
100 |
All |
50 Years and older (Adult, Senior) |
NCT03090854 |
K160402
2016-AO1639-42 |
CHOLINE |
September 1, 2017 |
September 1, 2019 |
September 1, 2019 |
March 27, 2017 |
August 29, 2017 |
|
- Centre Mémoire de Ressources et de Recherche Paris Nord
Paris, France
|
| 15 |
NCT02565511 |
Recruiting |
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease |
|
- Biological: CAD106 Immunotherapy
- Other: Placebo to CAD106
- Drug: CNP520
- Other: Placebo to CNP520
|
Interventional |
Phase 2
Phase 3 |
- Novartis Pharmaceuticals
- Banner Alzheimer's Institute
- National Institute on Aging (NIA)
- (and 3 more...)
|
Industry / Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Time to diagnosis of MCI due to Alzheimer's Disease (AD) or dementia due to Alzheimer's Disease
- Change in the Alzheimer's Prevention Initiative Composite Cognitive (APCC) Test Score
- Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) score
- (and 7 more...)
|
1340 |
All |
60 Years to 75 Years (Adult, Senior) |
NCT02565511 |
CAPI015A2201J
2015-002715-15
1UF1AG046150-01 |
Generation S1 |
November 30, 2015 |
August 30, 2024 |
September 2, 2024 |
October 1, 2015 |
April 18, 2018 |
|
- Banner Alzheimer's Institute
Phoenix, Arizona, United States - Mayo Clinic Arizona
Scottsdale, Arizona, United States - Banner Sun City Research Institute
Sun City, Arizona, United States - (and 73 more...)
|
| 16 |
NCT02947893 |
Recruiting |
Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease |
|
- Drug: Placebo Capsule(s) Once a Day by Mouth
- Drug: Nilotinib Capsule(s) Once a Day by Mouth
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Safety will be measured by number of participants experiencing the occurrence of adverse events and/or abnormal laboratory values
- Effects of Nilotinib treatment on measurement of Nilotinib in the CSF
|
42 |
All |
50 Years to 85 Years (Adult, Senior) |
NCT02947893 |
2016-0315 |
AD |
January 2017 |
February 2019 |
December 2019 |
October 28, 2016 |
February 20, 2018 |
|
- Georgetown University Medical Center
Washington, District of Columbia, United States
|
| 17 |
NCT00973518 |
Completed |
Improved Diagnosis of Alzheimer's Disease Using Magnetoencephalography (MEG) |
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Identification and characterization of patterns of correlated brain activity measured by MEG and the Orasi SNI test that differ consistently (e.g. at all evaluation time points) between HC and AD subjects
- Identification and characterization of patterns of correlated brain activity measured by MEG and the Orasi SNI test that differ across time points within single subjects and across groups of HC and AD subjects
- Identification and characterization of Orasi SNI test features that correlate with independent measures of cognitive function based on functional testing (ADAS-Cog sum of boxes, and MMSE raw score, One Card Learning Test)
- (and 2 more...)
|
160 |
All |
50 Years to 90 Years (Adult, Senior) |
NCT00973518 |
ADD 09-02 |
|
September 2009 |
June 2010 |
June 2010 |
September 9, 2009 |
August 13, 2010 |
|
- Rush Alzheimer's Disease Center
Chicago, Illinois, United States - Alexian Brothers Neuroscience Institute
Elk Grove Village, Illinois, United States
|
| 18 |
NCT03255720 |
Not yet recruiting |
Application of Diffusion Tensor Imaging in Alzheimer's Disease :Quantification of White Matter Micro-structural Changes |
|
|
Observational |
|
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- the extent of tissue damage of several brain white matter regions in patients with Alzheimer's disease.
|
40 |
All |
60 Years to 80 Years (Adult, Senior) |
NCT03255720 |
diffusion tensor imaging |
|
September 29, 2017 |
December 1, 2022 |
December 31, 2022 |
August 21, 2017 |
September 26, 2017 |
|
|
| 19 |
NCT02769234 |
Enrolling by invitation |
EEG/ERP Longitudinal Study in Alzheimer's Disease (AD) |
|
- Procedure: ERP/EEG test
- Procedure: Psychometric testing
|
Observational |
|
- Neuronetrix, Inc.
- Boston Center for Memory
- The Memory Clinic of Vermont
- Premiere Research Institute
|
Industry / Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Correlation (longitudinal change) between EEG/ERP vs. Neuropsychological Testing.
- Correlation (longitudinal change) between EEG/ERP vs ADNI-EF composite.
- Correlation (longitudinal change) between EEG/ERP vs. ADNI-Mem composite.
|
75 |
All |
60 Years to 95 Years (Adult, Senior) |
NCT02769234 |
SRP-1782 |
|
May 2016 |
June 2017 |
July 2017 |
May 11, 2016 |
May 30, 2017 |
|
- Premiere Research Institute
West Palm Beach, Florida, United States - Boston Center for Memory
Brookline, Massachusetts, United States - The Memory Clinic
Bennington, Vermont, United States
|
| 20 |
NCT01850238 |
Completed |
Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease |
|
- Biological: AADvac1
- Other: Placebo
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Tolerability and safety profile of AADvac1 in patients with mild-to-moderate Alzheimer's disease
- Immunogenicity of AADvac1
|
30 |
All |
50 Years to 85 Years (Adult, Senior) |
NCT01850238 |
AXON CO 18700
2012-003916-29 |
|
May 2013 |
March 2015 |
March 2015 |
May 9, 2013 |
October 12, 2015 |
|
- Medizinische Universitat Graz
Graz, Steiermark, Austria - Univeristätsklinik für Neurologie, PMU, Christian-Doppler Klinik
Salzburg, Austria - Medizinische Universitat Wien
Wien, Austria
|
| 21 |
NCT01409915 |
Active, not recruiting |
Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease |
|
- Drug: Sagramostim
- Drug: Saline -- placebo comparator
|
Interventional |
Phase 2 |
- University of Colorado, Denver
- The Dana Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Ability of Alzheimer's Disease subjects to tolerate Leukine treatment will be assessed
- Ability of Leukine treatment to improve cognition of Alzheimer's Disease subjects
|
40 |
All |
55 Years to 85 Years (Adult, Senior) |
NCT01409915 |
12-1273 |
|
March 2011 |
November 2018 |
November 2018 |
August 4, 2011 |
January 18, 2018 |
|
- University of Colorado Denver, Anschutz Medical Campus
Aurora, Colorado, United States
|
| 22 |
NCT03373604 |
Enrolling by invitation |
Imaging Tau in Alzheimer's Disease and Normal Aging |
|
- Drug: 18F-MK-6240
- Procedure: Lumbar Puncture (optional)
|
Interventional |
Phase 2 |
- William Charles Kreisl
- National Institute on Aging (NIA)
- Columbia University
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- 18F-MK-6240 binding (standardized uptake value ratio)
- Correlation of 18F-MK-6240 binding and CSF markers of neurodegeneration and inflammation.
|
175 |
All |
50 Years to 100 Years (Adult, Senior) |
NCT03373604 |
AAAR4352
K23AG052633-02 |
|
December 11, 2017 |
August 20, 2021 |
August 20, 2021 |
December 14, 2017 |
January 10, 2018 |
|
- Columbia University Medical Center
New York, New York, United States
|
| 23 |
NCT03507257 |
Not yet recruiting
New |
Longitudinal Early-onset Alzheimer's Disease Study Protocol |
- Early Onset Alzheimer Disease
- Alzheimer Disease
- Mild Cognitive Impairment
|
- Drug: Flortaucipir
- Drug: Florbetaben
|
Observational |
|
- Liana Apostolova
- Alzheimer's Therapeutic Research Institute
- National Institute on Aging (NIA)
- (and 2 more...)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Rate of change in cognition as measured by by the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog13)
- Rate of change in cognition as measured by the Clinical Dementia Rating - Sum of Boxes (CDR-SB)
- Rate of change in cognition as measured by the Clinician Judgment of Symptoms form from the NACC UDS.
- (and 5 more...)
|
500 |
All |
40 Years to 64 Years (Adult) |
NCT03507257 |
ATRI-003
R56AG057195 |
LEADS |
May 1, 2018 |
August 31, 2022 |
August 31, 2023 |
April 25, 2018 |
April 25, 2018 |
|
|
| 24 |
NCT02899091 |
Not yet recruiting |
Evaluation of the Safety and Potential Therapeutic Effects After Intravenous Transplantation of CB-AC-02 in Patients With Alzheimer's Disease |
|
- Biological: CB-AC-02
- Biological: Placebo
|
Interventional |
Phase 1
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Number of Adverse Events
- Changes from the baseline in ADAS-Cog (Azheimer's disease Assessment Scale - Congintive Subscale) Score
- Changes from the baseline in K-MMSE (Korean-Mini Mental Status Examination) Score
- (and 11 more...)
|
24 |
All |
50 Years and older (Adult, Senior) |
NCT02899091 |
CHA-PAD-101 |
|
September 2016 |
March 2018 |
June 2018 |
September 14, 2016 |
September 14, 2016 |
|
- Bundang Medical Center
Seongnam-si, Gyeonggi-do, Korea, Republic of
|
| 25 |
NCT02959489 |
Recruiting |
Risk Evaluation and Education for Alzheimer's Disease - the Study of Communicating Amyloid Neuroimaging (REVEAL-SCAN) |
- Alzheimer Disease
- Amyloid Beta-Peptides
- Risk Assessment
- (and 3 more...)
|
- Behavioral: Alzheimer's Disease Risk Disclosure
- Behavioral: Amyloid Brain Imaging and Alzheimer's Disease Risk Disclosure
|
Interventional |
Not Applicable |
- Brigham and Women's Hospital
- University of Pennsylvania
- University of Michigan
- (and 3 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Change in baseline neuropsychological performance compared to 6 weeks and 6 months post-disclosure
- Change in baseline measure scores on scales and questionnaires of psychological distress compared to 6 weeks and 6 months post-disclosure.
- Change in baseline measures of health behaviors compared to 6 weeks and 6 months post-disclosure to determine the type and frequency of behavior changes in response to learning risk information.
|
270 |
All |
65 Years to 80 Years (Adult, Senior) |
NCT02959489 |
RF1AG047866
1RF1AG047866-01A1 |
REVEAL-SCAN |
November 2016 |
July 2019 |
July 2019 |
November 9, 2016 |
December 20, 2016 |
|
- Brigham and Women's Hospital
Boston, Massachusetts, United States - University of Michigan
Ann Arbor, Michigan, United States - Duke University
Durham, North Carolina, United States - University of Pennsylvania
Philadelphia, Pennsylvania, United States
|
| 26 |
NCT03136679 |
Recruiting |
Discovery of Novel Biomarkers That Will Lead to the Early Detection of Alzheimer's Disease |
- Mild Cognitive Impairment
- Alzheimer Disease
|
|
Observational |
|
- Baylor Research Institute
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Discovery of novel biomarkers that will lead to the early detection of Alzheimer's disease.
|
220 |
All |
40 Years and older (Adult, Senior) |
NCT03136679 |
017-039 |
BVB |
March 22, 2017 |
April 30, 2019 |
December 31, 2019 |
May 2, 2017 |
May 4, 2017 |
|
- Baylor AT&T Memory Center
Dallas, Texas, United States
|
| 27 |
NCT02377206 |
Unknown † |
Neuroinflammation and Cognitive Decline in Alzheimer Disease |
|
- Other: ADAS-Cog evaluation
|
Interventional |
Phase 1 |
- University Hospital, Tours
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Change from baseline in ADAS-Cog score
- Quantification of neuroinflammation by [18F]DPA-714 PET imaging
|
45 |
All |
60 Years to 85 Years (Adult, Senior) |
NCT02377206 |
PRTS13-CH / NICAD |
NICAD |
March 2015 |
March 2017 |
March 2017 |
March 3, 2015 |
June 23, 2015 |
|
- University hospital of Caen
Caen, France - university hospital of Nantes
Nantes, France - University Hospital of Rennes
Rennes, France - University Hospital of Tours
Tours, France
|
| 28 |
NCT00876863 |
Active, not recruiting |
Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease |
|
- Genetic: CERE-110: Adeno-Associated Virus Delivery of NGF
- Procedure: Placebo Surgery
|
Interventional |
Phase 2 |
- Sangamo Therapeutics
- Alzheimer's Disease Cooperative Study (ADCS)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)
- Neuropsychological Test Battery
- Mini-Mental State Examination (MMSE)
- (and 2 more...)
|
50 |
All |
55 Years to 80 Years (Adult, Senior) |
NCT00876863 |
CERE-110-03
NIH Grant 1R01AG030048-01A1 |
|
September 2009 |
December 2019 |
March 2020 |
April 7, 2009 |
January 10, 2017 |
|
- University of Alabama
Birmingham, Alabama, United States - University of California, Los Angeles
Los Angeles, California, United States - University of California, San Diego
San Diego, California, United States - (and 7 more...)
|
| 29 |
NCT02208193 |
Unknown † |
Alzheimer's Disease, Art and Garden |
|
- Behavioral: Cognitive and psycho-behavioral effects of an artistic dimension
|
Interventional |
Not Applicable |
- Central Hospital, Nancy, France
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Comparaison of the number of language acts in each category between AD and controls subjects
- Scores obtained in standard neuropsychological tests, in particular to assess spatio-temporal orientation (Folstein MMSE),
- Scores obtained with the " MemoArtZ " tool (MAZ) to evaluate the memorization of artistic elements of the garden,
- (and 3 more...)
|
60 |
All |
60 Years and older (Adult, Senior) |
NCT02208193 |
2014-A00139-38 |
JAZ ART |
July 2014 |
October 2016 |
September 2017 |
August 4, 2014 |
July 30, 2015 |
|
|
| 30 |
NCT02031198 |
Completed |
18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease |
|
|
Interventional |
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Tolerability and safety profile of AADvac1 in patients with mild-to-moderate Alzheimer's disease
- Immunogenicity of AADvac1
- Patient cognition
|
25 |
All |
50 Years to 86 Years (Adult, Senior) |
NCT02031198 |
AC-AD-002
2013-004499-36 |
FUNDAMANT |
January 2014 |
August 2016 |
December 2016 |
January 9, 2014 |
March 17, 2017 |
|
- Medizinische Universitat Graz
Graz, Steiermark, Austria - Univeristätsklinik für Neurologie, PMU, Christian-Doppler Klinik
Salzburg, Austria - Medizinische Universitat Wien
Wien, Austria - Sozialmedizinisches Zentrum Ost (SMZ Ost) /Donauspital, Memory Clinic and Karl Landsteiner Institut for Amnestic disorders
Wien, Austria
|
| 31 |
NCT02884492 |
Active, not recruiting |
Imaging Tau in Alzheimer's Disease and Normal Aging |
|
- Drug: 18F-THK- 5351
- Procedure: Lumbar Puncture (optional)
|
Interventional |
Phase 2 |
- William Charles Kreisl
- National Institute on Aging (NIA)
- Columbia University
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- 18F-THK-5351 binding (standardized uptake value ratio)
- Cerebral spinal fluid (CSF) concentration of amyloid, tau, and inflammatory markers
|
60 |
All |
60 Years and older (Adult, Senior) |
NCT02884492 |
AAAQ7868
1K23AG052633-01 |
|
July 2016 |
June 2021 |
June 2021 |
August 31, 2016 |
December 13, 2017 |
|
- Columbia University Medical Center
New York, New York, United States
|
| 32 |
NCT02811653 |
Recruiting |
Motor Slowing and Its Lesion-related Correlates in Alzheimer's Disease |
|
- Device: Brain MRI
- Other: neuropsychological evaluation
- Biological: Blood
|
Interventional |
Not Applicable |
- Centre Hospitalier Universitaire, Amiens
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- median SRT (simple reaction time) to a stimulus (in milliseconds)
|
155 |
All |
40 Years to 85 Years (Adult, Senior) |
NCT02811653 |
PI2015_843_0003 |
TAMA |
December 2015 |
December 2019 |
December 2019 |
June 23, 2016 |
June 23, 2016 |
|
|
| 33 |
NCT02501876 |
Completed |
Type 2 Diabetes Mellitus as Catalyst for Alzheimer's Disease |
- Alzheimer´s Disease
- Diabetes Mellitus Type 2
|
- Other: There is a retrospectiv observational study. No intervention
|
Observational |
|
- Hospital Universitari Vall d'Hebron Research Institute
|
Other |
- Observational Model: Case-Control
- Time Perspective: Other
|
- The rate of conversion to Alzheimer's disease (AD)
- The presence of common alleles for Alzheimer's disease (AD) and Diabetes mellitus type 2
|
202 |
All |
65 Years to 90 Years (Adult, Senior) |
NCT02501876 |
PR(AG)32/2015 |
DIACEA |
May 2015 |
September 2015 |
May 2016 |
July 17, 2015 |
April 12, 2017 |
|
- Vall d´Hebron University Hospital
Barcelona, Spain
|
| 34 |
NCT00945672 |
Completed |
A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's Disease |
|
- Biological: PF-04360365 10 mg/kg
- Biological: PF-04360365 7.5 mg/kg
- Drug: placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Safety/tolerability/PK of multiple doses of PF-04360365 in subjects with mild to moderate Alzheimer's disease dosed for 1 year (adverse events, physical/neurological exams, vital signs, 12-lead ECG, clinical labs, brain MRI, cognitive assessments)
- Brain amyloid burden
- CSF abeta
- Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog); Disability Assessment for Dementia (DAD); plasma abeta, CSF tau and phosphotau; CSF protein, RBCs, WBCs and glucose; immunogenicity (anti-drug antibodies)
|
36 |
All |
50 Years and older (Adult, Senior) |
NCT00945672 |
A9951007 |
|
August 2009 |
June 2011 |
June 2011 |
July 24, 2009 |
May 5, 2016 |
|
- Pfizer Investigational Site
Göteborg, Sweden - Pfizer Investigational Site
Malmo, Sweden - Pfizer Investigational Site
Molndal, Sweden - Pfizer Investigational Site
Stockholm, Sweden
|
| 35 |
NCT01424436 |
Completed |
Modulation of Abeta Levels by GSK933776 in Alzheimer's Disease Patient |
|
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- The temporal changes of amyloid beta levels in CSF after GSK933776 single dose administration in the patients with Alzheimer's disease and Mild Cognitive impairment
- The temporal changes of total and free amyloid beta levels in plasma after GSK933776 single dose administration in the patients with Alzheimer's disease and Mild Cognitive impairment
- The temporal changes of Tau and phosphor Tau - 181 levels in CSF after GSK933776 single dose administration in the patients with Alzheimer's disease and Mild Cognitive impairment
- (and 2 more...)
|
19 |
All |
55 Years to 85 Years (Adult, Senior) |
NCT01424436 |
113043 |
|
May 19, 2010 |
December 8, 2011 |
December 8, 2011 |
August 29, 2011 |
June 14, 2017 |
|
- GSK Investigational Site
Mannheim, Baden-Wuerttemberg, Germany - GSK Investigational Site
Tuebingen, Baden-Wuerttemberg, Germany - GSK Investigational Site
Ulm, Baden-Wuerttemberg, Germany - (and 4 more...)
|
| 36 |
NCT01822951 |
Withdrawn |
Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT) |
|
- Drug: Cerebrolysin
- Drug: Donepezil
|
Interventional |
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change from Baseline in ADAS-cog. and CIBIC+ score distribution
- Adverse events
- Vital signs
- Laboratory tests
|
0 |
All |
50 Years and older (Adult, Senior) |
NCT01822951 |
EVE-AT-0412
2012-004944-31 |
DAT |
|
September 2016 |
December 2016 |
April 4, 2013 |
October 26, 2015 |
|
- AKh Allgemeines Krankenhaus der Stadt Linz GmbH
Linz, Austria
|
| 37 |
NCT01023867 |
Completed |
Clinical Trial of Donepezil Between the Patients With Alzheimer's Disease and Mixed Dementia |
- Alzheimer's Disease
- Dementia
|
|
Interventional |
Not Applicable |
- Samsung Medical Center
- Eisai Korea Inc.
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Alzheimer's Disease Assessment Scale-Cognitive, Korean version (ADAS-Cog-K)
- Seoul Activities of Daily Living (S-ADL)
- Seoul-Instrumental Activities of Daily Living (S-IADL)
- Korean Neuropsychiatric Inventory (K-NPI)
|
88 |
All |
Child, Adult, Senior |
NCT01023867 |
2007-03-039 |
|
March 2007 |
June 2010 |
June 2010 |
December 2, 2009 |
January 6, 2016 |
|
- Samsung Medical Center
Seoul City, Korea, Republic of
|
| 38 |
NCT02788513 |
Recruiting |
BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease. |
|
- Drug: BI 425809 dose 1
- Drug: BI 425809 dose 2
- Drug: BI 425809 dose 3
- (and 2 more...)
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- The change from baseline in ADAS-Cog11 (Alzheimer's Disease Assessment Scale-Cognitive subscale 11 item) total score
- Change from baseline in the ADCS-ADL (Alzheimer's Disease Cooperative Study/Activities of Daily Living) score
- CIBIC+ (Clinician's Interview-Based Impression of Change) score
|
585 |
All |
55 Years and older (Adult, Senior) |
NCT02788513 |
1346.23
2015-005438-24 |
|
August 11, 2016 |
August 15, 2020 |
September 15, 2020 |
June 2, 2016 |
April 17, 2018 |
|
- SALK Christian-Doppler-Klinik,Paracel.Med.Privatuni.f.Neurol
Salzburg, Austria - Medical Arts Health Research Group
Kelowna, British Columbia, Canada - True North Clinical Research Halifax, Inc.
Halifax, Nova Scotia, Canada - (and 10 more...)
|
| 39 |
NCT01569516 |
Unknown † |
Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease |
|
- Drug: Octohydroaminoacridine Succinate Tablets
- Drug: Octohydroaminoacridine succinate Tablets
- Drug: Placebo
|
Interventional |
Phase 2 |
- Changchun Huayang High-tech Co., Ltd
- Beijing Bionovo Medicine Development Co., Ltd.
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Alzheimer's Disease Assessment Scale - Cognitive Subscale
- Clinician's Interview Based Impression of Change, plus caregiver input
- Activities of Daily Living:Activities of Daily Living Scale（ADL)
- Mental behavior: neuropsychiatric questionnaire (NPI)
|
288 |
All |
50 Years to 85 Years (Adult, Senior) |
NCT01569516 |
CCHY2010L00161-HPAD2 |
|
June 2011 |
July 2012 |
October 2012 |
April 3, 2012 |
April 9, 2012 |
|
- Guangzhou Brain Hospital
Guangzhou, Guangdong, China - Affiliated Hospital of Guilin Medical University
Guilin, Guangxi, China - Hebei mental health center
Baoding, Hebei, China - (and 10 more...)
|
| 40 |
NCT02702817 |
Completed |
Randomized Trial of Low-dose Naproxen in Cognitively Intact Persons at Risk of Alzheimer's Dementia |
- Alzheimer Disease
- Cognitive Decline Due to Alzheimer Disease
- Mild Cognitive Impairment Due to Alzheimer Disease
|
- Drug: Naproxen
- Drug: Placebo
|
Interventional |
Phase 2 |
- Douglas Mental Health University Institute
- McGill University
- Johns Hopkins University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Trajectory of composite Alzheimer Progression Score (APS) from multiple cognitive and biomarker measures of pre-clinical Alzheimer's disease
- frequency and severity of treatment-emergent adverse events
- trajectory of cognitive abilities measured by global score on Repeatable Battery for Assessment of Neuropsychological Status
- (and 3 more...)
|
200 |
All |
55 Years and older (Adult, Senior) |
NCT02702817 |
INTREPAD |
|
August 1, 2012 |
March 31, 2017 |
July 15, 2017 |
March 9, 2016 |
August 1, 2017 |
|
- Douglas Hospital Research Centre
Montreal, Quebec, Canada
|
| 41 |
NCT02537496 |
Recruiting |
Enhancing Working Memory in Patients With Early Alzheimer's Disease Through the Use of rTMS |
|
- Procedure: Repetitive Transcranial Magnetic Stimulation
- Procedure: Repetitive Transcranial Magnetic Stimulation - Sham
|
Interventional |
Not Applicable |
- Centre for Addiction and Mental Health
- Brain & Behavior Research Foundation
- University of Toronto
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in N-back Task Performance
- Changes in Theta Phase-Gamma Amplitude Coupling
- Changes in DLPFC Neuroplasticity
- (and 2 more...)
|
36 |
All |
55 Years and older (Adult, Senior) |
NCT02537496 |
005/2015 |
rTMS-AD |
August 2015 |
August 2018 |
August 2018 |
September 1, 2015 |
January 23, 2018 |
|
- Center for Addiction and Mental Health
Toronto, Ontario, Canada
|
| 42 |
NCT02972658 |
Enrolling by invitation |
A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia |
|
|
Interventional |
Phase 3 |
- Eli Lilly and Company
- AstraZeneca
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Delayed Start Analysis on the 13-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13)
- Delayed Start Analysis on the Alzheimer´s Disease Cooperative Study Activities of Daily Living Inventory (ADCS-iADL) Instrumental Items
- Delayed Start Analysis on the Functional Activities Questionnaire (FAQ) Score
- (and 3 more...)
|
1400 |
All |
55 Years and older (Adult, Senior) |
NCT02972658 |
16557
I8D-MC-AZFD
2016-003440-36 |
|
March 15, 2017 |
September 30, 2021 |
September 30, 2021 |
November 23, 2016 |
April 19, 2018 |
|
- Banner Alzheimer's Institute
Phoenix, Arizona, United States - Territory Neurology & Research Institute
Tucson, Arizona, United States - Senior Clinical Trials, Inc.
Laguna Hills, California, United States - (and 203 more...)
|
| 43 |
NCT00722046 |
Completed |
Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease |
|
- Biological: PF-04360365 0.1 mg/kg
- Biological: PF-04360365 0.5 mg/kg
- Biological: PF-04360365 1 mg/kg
- (and 3 more...)
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Safety/tolerability of PF-04360365 in subjects with mild to moderate Alzheimer's disease dosed for 18 months. (adverse events, physical/neurologic exams, vital signs, 12-lead ECG, clinical labs, brain MRI, cognitive assessments)
- Pharmacokinetics of PF-04360365 following administration of multiple doses in subjects with mild to moderate Alzheimer's disease. (plasma and cerebrospinal fluid (as available) PF-04360365 concentrations)
- Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog); Disability Assessment for Dementia (DAD); plasma/CSF Abeta; CSF tau and phosphotau; CSF protein, RBCs, WBCs and glucose; Immunogenicity (anti-drug antibodies)
|
198 |
All |
50 Years and older (Adult, Senior) |
NCT00722046 |
A9951002 |
|
December 2008 |
August 2011 |
August 2011 |
July 25, 2008 |
May 5, 2016 |
|
- Pfizer Investigational Site
Peoria, Arizona, United States - Pfizer Investigational Site
Phoenix, Arizona, United States - Pfizer Investigational Site
Miami, Florida, United States - (and 35 more...)
|
| 44 |
NCT01125631 |
Completed |
Multiple Intravenous Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease |
|
- Biological: PF-04360365 8.5 mg/kg
- Drug: Placebo
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Safety of PF-04360365 in Japanese subjects with mild to moderate Alzheimer's disease dosed for 6 months. (adverse events, physical/neurologic exams, vital signs, 12-lead ECG, clinical labs, brain MRI, immunogenicity and cognitive assessments)
- Pharmacokinetics of PF-04360365 following administration of multiple doses in Japanese subjects with mild to moderate Alzheimer's disease. (plasma PF-04360365 concentrations)
- Plasma concentration of Aβ species following administration of multiple doses of PF-04360365 in Japanese subjects with mild to moderate Alzheimer's disease.
|
8 |
All |
50 Years and older (Adult, Senior) |
NCT01125631 |
A9951016 |
|
May 2010 |
August 2011 |
August 2011 |
May 18, 2010 |
August 12, 2011 |
|
- Pfizer Investigational Site
Hirosaki, Aomori, Japan - Pfizer Investigational Site
Fukuoka-shi, Fukuoka, Japan - Pfizer Investigational Site
Fukuyama city, Hiroshima, Japan - Pfizer Investigational Site
Kanazawa, Ishikawa, Japan
|
| 45 |
NCT02292238 |
Recruiting |
Benfotiamine in Alzheimer's Disease: A Pilot Study |
|
|
Interventional |
Phase 2 |
- Burke Medical Research Institute
- Burke Rehabilitation Hospital
- Columbia University
- (and 2 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- ADAS-cog as the primary clinical outcome
- Brain glucose utilization
- Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)
- (and 3 more...)
|
76 |
All |
60 Years to 95 Years (Adult, Senior) |
NCT02292238 |
BRC-451
1R01AG043679-01A1 |
Benfotiamine |
November 2014 |
November 2018 |
November 2019 |
November 17, 2014 |
January 17, 2018 |
|
- Burke
White Plains, New York, United States
|
| 46 |
NCT03455569 |
Not yet recruiting |
A Dyadic Sleep Intervention for Alzheimer's Disease Patients and Their Caregivers |
|
- Behavioral: Behavioral sleep education
- Behavioral: Education only
|
Interventional |
Not Applicable |
- University of California, Los Angeles
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Health Services Research
|
- Sleep efficiency for Alzheimer's disease patients
- Total wake time for Alzheimer's disease patients
- Sleep quality for caregivers
- (and 8 more...)
|
80 |
All |
60 Years and older (Adult, Senior) |
NCT03455569 |
1K23AG055668-01 |
|
May 1, 2018 |
October 30, 2021 |
April 30, 2022 |
March 6, 2018 |
March 6, 2018 |
|
- University of California Los Angeles
Los Angeles, California, United States - Veterans Affairs Greater Los Angeles Healthcare System
North Hills, California, United States
|
| 47 |
NCT02711683 |
Recruiting |
DL-3-n-butylphthalide Treatment in Patients With Mild to Moderate Alzheimer's Disease Already Receiving Donepezil |
|
- Drug: DL-3-n-butylphthalide
- Drug: Donepezil
|
Observational |
|
- First Affiliated Hospital Xi'an Jiaotong University
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Alzheimer's disease assessment scale-cognitive subscale (ADAS-cog)
- Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-plus)
- Alzheimer's Disease Cooperative Study-Activities of Daily Living(ADCS-ADL)
- Neuropsychiatric Inventory(NPI)
|
120 |
All |
50 Years to 85 Years (Adult, Senior) |
NCT02711683 |
XJTU1AF-CRF-2015-027 |
|
March 2016 |
January 2018 |
March 2018 |
March 17, 2016 |
February 7, 2017 |
|
- First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China
|
| 48 |
NCT02925650 |
Recruiting |
Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease |
|
- Drug: Posiphen
- Drug: Placebo
|
Interventional |
Phase 1
Phase 2 |
- QR Pharma Inc.
- Alzheimer's Disease Cooperative Study (ADCS)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Safety and Tolerability: Reports of adverse events or study discontinuations
- AUC of Posiphen and its metabolites in plasma and CSF
- Fractional synthesis rate of Aβ40 in CSF using the SILK™ technique
- (and 4 more...)
|
24 |
All |
55 Years to 85 Years (Adult, Senior) |
NCT02925650 |
QR15001
ADC-042-DISC |
DISCOVER |
March 2, 2017 |
December 31, 2019 |
December 31, 2019 |
October 6, 2016 |
April 4, 2018 |
|
- UCSD Alzheimer's Disease Research Center
La Jolla, California, United States - IU Health Partners, Adult Neurology Clinic
Indianapolis, Indiana, United States - Johns Hopkins Hospital
Baltimore, Maryland, United States - Washington University Sleep Medicine Center
Brentwood, Missouri, United States
|
| 49 |
NCT02709356 |
Recruiting |
Medium Chain Triglycerides and Brain Metabolism in Alzheimer's Disease |
|
- Dietary Supplement: 1-month of 60-40 MCT oil
- Dietary Supplement: 1-month of C8 MCT oil
|
Interventional |
Not Applicable |
- Université de Sherbrooke
- Fondation Vitae
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Quantification of brain glucose uptake
- Quantification of brain acetoacetate uptake
|
20 |
All |
65 Years and older (Adult, Senior) |
NCT02709356 |
2016-547 |
MCT-MA |
October 2015 |
December 2018 |
December 2018 |
March 16, 2016 |
December 21, 2017 |
|
- Research Centre on Aging (CSSS-IUGS - CIUSSS de l'Estrie - CHUS)
Sherbrooke, Quebec, Canada
|
| 50 |
NCT02245737 |
Active, not recruiting |
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease |
|
- Drug: Lanabecestat
- Drug: Placebo
|
Interventional |
Phase 2
Phase 3 |
- Eli Lilly and Company
- AstraZeneca
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change from Baseline on the 13-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13)
- Change from Baseline on the Alzheimer´s Disease Cooperative Study Activities of Daily Living Inventory (ADCS-iADL) Instrumental Items
- Change from Baseline on the Functional Activities Questionnaire (FAQ) Score
- (and 15 more...)
|
2202 |
All |
55 Years to 85 Years (Adult, Senior) |
NCT02245737 |
16023
I8D-MC-AZES
2014-002601-38
D5010C00009 |
AMARANTH |
September 2014 |
September 2019 |
September 2019 |
September 22, 2014 |
March 23, 2018 |
|
- Banner Alzheimer's Institute
Phoenix, Arizona, United States - St Josephs Hospital and Medical Center
Phoenix, Arizona, United States - Banner Sun Health Research Institute
Sun City, Arizona, United States - (and 260 more...)
|
Create an RSS feed from your search for:
Download the search results for: